Migraine Headache and the Risk of Depression - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36475133/
A neurological disorder that commonly causes disability is migraine. Numerous studies have shown that mood disorders and migraines are often co-occurring, and these individuals are more likely to have a migraine-related disability. This research has shown that it is beneficial to prevent psychiatri ...
Conclusions: A neurological disorder that commonly causes disability is migraine. Numerous studies have shown that mood disorders and migraines are often co-occurring, and these individuals are more likely to have a migraine-related disability. This research has shown that it is beneficial to prevent psychiatric comorbidity by using PHQ-9 as a regular screening tool for migraine patients.
Share
-
Huma Sheikh, CEO, NY Neurology Medicine, PCJanuary 09, 2023Important information.
-
Dr HamidDecember 21, 2022Anxiety and depression are typical psychiatric comorbidities among migraineurs.
Caffeine consumption as a risk factor for childhood and adolescence migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36461769/
31 of 40 (77.5%) cases of childhood/ adolescence migraine showed serum and urine caffeine-positivity based on LC-MS/MS. HIT-6 score, a measure of headache severity, was significantly higher for caffeine-positive vs....
Conclusions: 31 of 40 (77.5%) cases of childhood/ adolescence migraine showed serum and urine caffeine-positivity based on LC-MS/MS. HIT-6 score, a measure of headache severity, was significantly higher for caffeine-positive vs. -negative cases. Symptoms of childhood/ adolescence migraine were exacerbated by caffeine consumption.
Share
-
Huma Sheikh, CEO, NY Neurology Medicine, PCJanuary 09, 2023Very interesting, I wonder if one is associated or brings on migraine phenotype quicker.
-
Dr HamidDecember 21, 2022Interesting article on associations between serum and urine caffeine levels and headache severity in childhood and adolescence migraine cases
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36538908/
The aim of the present study was to assess erenumab efficacy in migraine disability and intensity throughout the first treatment cycle, discontinuation, and the first 6 months of re-treatment in patients with high-frequency episodic migraine. The study design was retrospective and observational. Inc ...
Conclusions: During re-treatment with erenumab 140 mg, migraine pain intensity and disability documented a significant and progressive improvement. Our data confirm the long-term efficacy, although in a very limited case series, of monoclonal antibodies targeting CGRP beyond headache frequency reduction.
-
Huma Sheikh, CEO, NY Neurology Medicine, PCJanuary 09, 2023great information.
OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36548744/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Our results advocate in favor of the view that dual therapy is effective and should be considered in difficult-to-treat CM patients who have failed all available monotherapies.
Share
-
Huma Sheikh, CEO, NY Neurology Medicine, PCJanuary 09, 2023Yes we do this now, hopefully insurances will pay.
How the COVID-19 emergency changed our modality to treat patients with migraine: a positive aspect of the pandemic - Neurological Sciences
Source : https://link.springer.com/article/10.1007/s10072-022-06585-9
Migraine patients experienced a significant impact due to the coronavirus 2019 disease (COVID-19) pandemic; maintaining optimal access to needed care was challenging. Migraine management, which is often difficult under normal circumstances, became very complex during the COVID-19 pandemic, mainly due to the widespread limitations on mobility.
Conclusions: Our conclusion is that the BeHome program seems to have been feasible, effective, and sustainable during the COVID-19 pandemic emergency, but could also be very helpful in regular clinical practice as an innovative approach to the management of adults with CM-MOH and adolescents with HEFM and CM. Although this analysis was conducted on a portion of the sample and on interim time points, it has to be noted that none of the patients was lost to follow-up."
Share
-
Huma Sheikh, CEO, NY Neurology Medicine, PCJanuary 09, 2023I hope we can keep up with this.